Funding

#Bill & Melinda Gates Foundation #Funding #Genetic medicines #Sickle cell disorder (SCD) #Tessera Therapeutics

Investment to develop in vivo genetic treatment for sickle cell disease

Tessera Therapeutics, a biotech developing a new approach to genome engineering, has entered into an agreement with the Bill & Melinda Gates Foundation to jointly fund the company’s in vivo programme for sickle cell disease (SCD). The funding includes an initial investment, with potential total investment of up to $50… Read More

#News

AI concept
#Artificial intelligence (AI) #Cradle #Drug discovery #Funding #Machine learning #Protein engineering

Generative AI unlock the impact of engineered biology

Cradle, an AI-powered platform for protein engineering, has raised $73m in Series B funding to respond to rising demand in R&D intensive industries. This funding takes the total raised to date over $100m. The round was led by IVP with participation from previous investors Index Ventures and Kindred Capital. Proteins… Read More

#Business & Investment #News

Bacteria
#Antimicrobials #Centauri Therapeutics #Funding #Immunotherapy

Centauri awarded £1m for immunotherapeutic technology

Immunotherapy developer Centauri Therapeutics has been awarded a £1 ($1.2) million grant by Pathways to Antimicrobial Clinical Efficacy (PACE), an initiative focused on early-stage antimicrobial drug and diagnostic discovery.   The funding will support the continued development of Centauri’s Alphamer technology, in this case targeting gram-negative bacteria including multi-drug resistant (MDR)… Read More

#Business & Investment #News

Woman tests blood glucose level
#AdipoPharma #Biotech #Clinical trials #France #Funding #Type 2 diabetes

Investments pave way for type 2 diabetes breakthrough 

French biotech AdipoPharma is developing a novel and promising type 2 diabetes drug, for which it has successfully secured the funding needed to begin Phase I clinical trials. The company expects to begin clinical trials in the US in mid-2025.     This funding will enable AdipoPharma to accelerate… Read More

#News

GBP pound sterling funding
#Antibiotic resistance #Antimicrobial resistance (AMR) #Financing #Funding #Glox Therapeutics

£1 million PACE grant to accelerate precision antibiotics 

Glox Therapeutics has secured £1 million in grant funding from Pathways to Antimicrobial Clinical Efficacy (PACE), one of the UK’s largest public-private initiatives targeting early-stage antimicrobial medicines and diagnostic discovery.   The funding will help to accelerate the development of Glox Therapeutics’ novel antibiotics targeting drug-resistant pathogenic bacteria, Escherichia coli… Read More

#Business & Investment #News

#Finance #Funding #Investment #Neurodegenerative disorders #Neuroscience #Private investment

New DDW Highlights episode: 11 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK regulator NICE,… Read More

#News

#Finance #Funding #Investment #Neurodegenerative disorders #Neuroscience #Private investment

This week in drug discovery (4-8 November) 

News round-up for 4-8 November by DDW Senior Digital Content Editor Diana Spencer. This week DDW has reported on significant investment in the development of treatments for neurodegenerative diseases, but also gene therapies for CNS disorders and radioligand-based therapies for cancer. The top stories:… Read More

#News

#Dementia #Funding #Investment #Parkinson's #UK Dementia Research Institute

£20m funding offered to advance breakthroughs in dementia research

The UK Dementia Research Institute has received major new government funding to boost translational research into dementia and related neurodegenerative conditions such as Parkinson’s and motor neuron disease. The UK-wide research institute will receive an initial £20 ($25.9) million from the National Institute for Health and… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

New DDW Highlights episode: 4 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

This week in drug discovery (28 Oct – 1 Nov) 

News round-up for 28 Oct – 1 Nov by DDW Senior Digital Content Editor Diana Spencer. In a week that saw a second monoclonal antibody rejected by UK regulator NICE, antibodies have been high on the news agenda. More positively, a new indication for Fasenra was approved in… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

New DDW Highlights episode: 29 October 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With a presidential election just round the corner in the US and… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

This week in drug discovery (21-25 October) 

News round-up for 21-25 October by DDW Senior Digital Content Editor Diana Spencer. With a presidential election just round the corner in the US and a new UK budget on the way, financial support for life sciences is high on the agenda, so the news round-up this week… Read More

#News

Quantum drug discovery
#Funding #Genetics / genomics #Muscular dystrophy #Quantum computing #University of Nottingham

Funding supports quantum drug discovery for myotonic dystrophy

A team of researchers from the University of Nottingham have received funding to explore the capabilities of quantum computing for developing new drugs for myotonic dystrophy. Building on an initial award of over £1 ($1.3) million, a team of researchers from the University of Nottingham, with… Read More

#News

#Biological threats #Covid-19 #European Commission #Fabentech #Funding #Pandemic response

€20 million EIB financing to combat biological threats

The European Investment Bank (EIB) and the French biopharmaceutical company Fabentech have signed a €20 million loan to accelerate the development of broad-spectrum therapeutics to combat biological threats to public health. The deal is supported by the Health Emergency Preparedness and Response Authority (HERA), set up… Read More

#News

#Cystic fibrosis #Financing #Funding #Neuroscience #Oncology #Rare disease

This week in drug discovery (30 Sept – 4 Oct) 

News round-up for 30 Sept – 4 Oct by DDW Senior Digital Content Editor Diana Spencer. The theme of the news highlights this week is funding, with companies raising considerable levels of private investment, alongside new funding grants to advance the development of therapeutics for lung infections in… Read More

#News

Natural killer cells
#Cell therapy #Funding #Natural killer cells #NK:IO #Oncology

NK:IO progresses ovarian cancer natural killer therapy

Imperial College spin-out company NK:IO has completed a seed round to a total of £5.9 ($7.8) million. The round included additional funding from UK Innovation Science and Seed Fund (UKI2S), managed by Future Planet Capital, Cambridge Angels and Cancer Research Horizons. The company says the funds will be used to… Read More

#Business & Investment #Cancer Research #News